Meridian Bioscience Inc. said Thursday it has received Canadian regulatory approval to sell its illumigeneT molecular test for clostridium difficile, which can cause diarrhea and colon inflammation.
The company said the approval will help it meet the needs of its clinical laboratory customers. The product has been recently launched in the U.S. as well as in Australia, Taiwan and most European markets.
"Toxin producing C. difficile infections, especially in hospitalized patients, can have especially devastating consequences if not diagnosed and treated quickly," said CEO Jack Kraeutler, in a statement. "With minimal hands-on time and virtually no capital expense, illumigene gives any infectious disease lab access to a convenient and powerful DNA amplification platform."
In morning trading, shares rose 8 cents to $21.79.